PL2373681T3 - Kompozycje farmaceutyczne albiglutydu - Google Patents

Kompozycje farmaceutyczne albiglutydu

Info

Publication number
PL2373681T3
PL2373681T3 PL09832522T PL09832522T PL2373681T3 PL 2373681 T3 PL2373681 T3 PL 2373681T3 PL 09832522 T PL09832522 T PL 09832522T PL 09832522 T PL09832522 T PL 09832522T PL 2373681 T3 PL2373681 T3 PL 2373681T3
Authority
PL
Poland
Prior art keywords
albiglutide
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL09832522T
Other languages
English (en)
Inventor
Mark A. Bush
Murray W. Stewart
Yonghong Yang
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PL2373681T3 publication Critical patent/PL2373681T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL09832522T 2008-12-10 2009-12-10 Kompozycje farmaceutyczne albiglutydu PL2373681T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12122908P 2008-12-10 2008-12-10
US15090909P 2009-02-09 2009-02-09
US16399509P 2009-03-27 2009-03-27
US23872309P 2009-09-01 2009-09-01
EP09832522.8A EP2373681B1 (en) 2008-12-10 2009-12-10 Pharmaceutical compositions of albiglutide

Publications (1)

Publication Number Publication Date
PL2373681T3 true PL2373681T3 (pl) 2017-07-31

Family

ID=42243062

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09832522T PL2373681T3 (pl) 2008-12-10 2009-12-10 Kompozycje farmaceutyczne albiglutydu

Country Status (14)

Country Link
US (3) US8748377B2 (pl)
EP (1) EP2373681B1 (pl)
JP (1) JP2012511586A (pl)
CY (1) CY1118731T1 (pl)
DK (1) DK2373681T3 (pl)
ES (1) ES2620610T3 (pl)
HR (1) HRP20170478T1 (pl)
HU (1) HUE031900T2 (pl)
LT (1) LT2373681T (pl)
PL (1) PL2373681T3 (pl)
PT (1) PT2373681T (pl)
SI (1) SI2373681T1 (pl)
SM (1) SMT201700189T1 (pl)
WO (1) WO2010068735A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu
WO2011140176A1 (en) 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
HRP20251088T1 (hr) 2012-07-01 2025-11-07 Novo Nordisk A/S Upotreba dugodjelujućih peptida glp‑1
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
SG10201705097PA (en) 2012-12-21 2017-07-28 Sanofi Sa Functionalized exendin-4 derivatives
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
LT3004155T (lt) 2013-05-28 2021-12-27 Takeda Pharmaceutical Company Limited Peptidų junginys
US20140378374A1 (en) * 2013-06-21 2014-12-25 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treatment
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2015200324A1 (en) * 2014-06-25 2015-12-30 Glaxosmithkline Llc Pharmaceutical compositions
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN109477094B (zh) 2016-05-24 2022-04-26 武田药品工业株式会社 肽化合物
WO2019060653A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF
IL322969A (en) 2017-10-12 2025-10-01 Novo Nordisk As Semaglutide in medical therapy
KR20250075642A (ko) 2022-09-21 2025-05-28 리제너론 파아마슈티컬스, 인크. 비만, 당뇨병 및 간 기능 장애를 치료하는 방법

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69129226T2 (de) * 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ES2359031T3 (es) 1996-08-08 2011-05-17 Amylin Pharmaceuticals, Inc. Composición farmacéutica que comprende un péptido de exendina-4.
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1180121B9 (en) 1999-05-17 2004-09-08 Conjuchem, Inc. Long lasting insulinotropic peptides
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
PT1324776E (pt) 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
WO2002034285A2 (en) 2000-10-20 2002-05-02 Coolidge Thomas R Treatment of hibernating myocardium and diabetic cardiomyopathy with a glp-1 peptide
UA93662C2 (uk) 2000-12-07 2011-03-10 Эли Лилли Энд Компани Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
EP1390061A2 (en) 2000-12-13 2004-02-25 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
HUP0700151A2 (en) 2001-10-18 2007-05-29 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
MXPA04006679A (es) 2002-01-08 2004-11-10 Lilly Co Eli Analogos extendidos de peptido-1 de tipo glucagon.
JP2005535569A (ja) 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー／エス Ｇｌｐ−１アゴニスト及び心臓血管合併症
US7790681B2 (en) 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
EP1610811A4 (en) 2002-12-17 2008-03-26 Amylin Pharmaceuticals Inc PREVENTION AND TREATMENT OF CARDIAC ARRHYTHMIAS
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP1729795B1 (en) 2004-02-09 2016-02-03 Human Genome Sciences, Inc. Albumin fusion proteins
JP2008501765A (ja) 2004-06-11 2008-01-24 ノボ　ノルディスク　アクティーゼルスカブ Ｇｌｐ−１アゴニストを用いた薬剤誘発性肥満の中和
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
CA2592065A1 (en) 2004-12-22 2007-04-26 Centocor, Inc. Glp-1 agonists, compositions, methods and uses
AU2005323063B2 (en) 2004-12-24 2011-01-27 Amylin Pharmaceuticals, Llc Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
WO2006105527A2 (en) 2005-03-31 2006-10-05 Amylin Pharmaceuticals, Inc. Amylin and amylin agonists for treating psychiatric diseases and disorders
US20080200383A1 (en) * 2005-04-08 2008-08-21 Amylin Pharmaceuticals, Inc. Pharmaceutical Formulations Comprising Incretin Peptide and Aprotic Polar Solvent
US8946149B2 (en) 2005-04-11 2015-02-03 Amylin Pharmaceuticals, Llc Use of exendin and analogs thereof to delay or prevent cardiac remodeling
JP2009514900A (ja) 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
KR20090031368A (ko) 2006-05-26 2009-03-25 아밀린 파마슈티칼스, 인크. 울혈성 심부전 치료용 조성물 및 방법
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
BRPI0714334A2 (pt) 2006-07-18 2013-05-14 Centocor Inc mimeticorpos de glp-1 humano aperfeiÇoados, composiÇÕes, mÉtodos e usos
WO2008019143A2 (en) 2006-08-04 2008-02-14 Amylin Pharmaceuticals, Inc Use of exendins and glp-i receptor agonists for altering lipoprotein particle size and subclass composition
PE20121528A1 (es) * 2006-09-13 2012-12-12 Smithkline Beecham Corp Metodos para administrar agentes hipoglucemiantes de larga duracion
EP2163243A1 (en) 2008-09-12 2010-03-17 Biocompatibles UK Limited Treatment of acute myocardial infarction (AMI) using encapsulated cells encoding and secreting GLP-1 peptides or analogs thereof
PL2373681T3 (pl) 2008-12-10 2017-07-31 Glaxosmithkline Llc Kompozycje farmaceutyczne albiglutydu

Also Published As

Publication number Publication date
DK2373681T3 (en) 2017-04-24
EP2373681A4 (en) 2013-11-06
HRP20170478T1 (hr) 2017-05-19
ES2620610T3 (es) 2017-06-29
EP2373681B1 (en) 2017-01-18
LT2373681T (lt) 2017-04-10
US8748377B2 (en) 2014-06-10
US20140228288A1 (en) 2014-08-14
PT2373681T (pt) 2017-04-11
US20140228284A1 (en) 2014-08-14
US20110301080A1 (en) 2011-12-08
CY1118731T1 (el) 2017-07-12
JP2012511586A (ja) 2012-05-24
HUE031900T2 (en) 2017-08-28
WO2010068735A1 (en) 2010-06-17
SI2373681T1 (sl) 2017-05-31
SMT201700189T1 (it) 2017-05-08
EP2373681A1 (en) 2011-10-12

Similar Documents

Publication Publication Date Title
PT2373681T (pt) Composições farmacêuticas de albiglutida
GB0814695D0 (en) Pharmaceutical compositions
PT2323623T (pt) Composições farmacêuticas
IL228817A0 (en) Pharmaceutical compounds
IL211886A0 (en) Solid pharmaceutical composition
IL208387A0 (en) Pharmaceutical composition
ZA201104670B (en) Pharmaceutical composition comprising aleglitazar
ZA201100871B (en) Solid pharmaceutical composition
EP2296687A4 (en) PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
ZA201006224B (en) Pharmaceutical composition
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
IL206487A0 (en) Pharmaceutical compositions
GB2464200B (en) Pharmaceutical composition
GB0902648D0 (en) Pharmaceutical compounds and compositions
GB0817969D0 (en) Pharmaceutical composition
GB0908317D0 (en) Pharmaceutical compounds and compositions
GB0800659D0 (en) Pharmaceutical Compositions
EP2236135A4 (en) STABLE PHARMACEUTICAL COMPOSITION
GB0805807D0 (en) Novel pharmaceutical compositions
GB0804485D0 (en) Novel pharmaceutical compositions
GB0806156D0 (en) Pharmaceutical compositions
GB0802024D0 (en) Pharmaceutical compositions
GB0806283D0 (en) Pharmaceutical compositions
EP2308842A4 (en) PHARMACEUTICAL COMPOSITIONS
HU0800741D0 (en) Improved pharmaceutical composition